Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

被引：0
作者：
Kim Dalziel
Ali Round
Ruth Garside
Ken Stein
机构：
[1] Peninsula Medical School,Peninsula Technology Assessment Group
[2] Universities of Exeter and Plymouth,Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Imatinib; Bone Marrow Transplantation; Chronic Myeloid Leukaemia; Blast Crisis; Cytogenetic Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.
引用
收藏
页码：515 / 526
页数：11
相关论文
共 50 条
  • [41] Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
    Husaini, Roslina
    Ahmad, Munirah
    Zakaria, Zubaidah
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 3209 - 3216
  • [42] Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Giralt, Sergio A.
    Arora, Mukta
    Goldman, John M.
    Lee, Stephanie J.
    Maziarz, Richard T.
    McCarthy, Philip L.
    Sobocinski, Kathleen A.
    Horowitz, Mary M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) : 461 - 467
  • [43] Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
    Marin, D
    Marktel, S
    Bua, M
    Szydlo, RM
    Franceschino, A
    Nathan, I
    Foot, N
    Crawley, C
    Nakorn, TN
    Olavarria, E
    Lennard, A
    Neylon, A
    O'Brien, SG
    Goldman, JM
    Apperley, JF
    LEUKEMIA, 2003, 17 (08) : 1448 - 1453
  • [44] Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
    D Marin
    S Marktel
    M Bua
    R M Szydlo
    A Franceschino
    I Nathan
    N Foot
    C Crawley
    T Na Nakorn
    E Olavarria
    A Lennard
    A Neylon
    S G O'Brien
    J M Goldman
    J F Apperley
    Leukemia, 2003, 17 : 1448 - 1453
  • [45] Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
    Doggrell, S
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (08) : 1063 - 1066
  • [46] Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
    Kevin Marsh
    Peng Xu
    Panagiotis Orfanos
    Agnes Benedict
    Kamal Desai
    Ingolf Griebsch
    PharmacoEconomics, 2014, 32 : 853 - 864
  • [47] Chronic myeloid leukemia: First-line drug of choice
    Jabbour, Elias
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (01) : 59 - 66
  • [48] Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure
    Gomez-Almaguer, David
    Saldana-Vazquez, Roxana
    Tarin-Arzaga, Luz
    Angel Herrera-Rojas, Miguel
    Vazquez-Mellado de Larracoechea, Alberto
    Graciela Cantu-Rodriguez, Olga
    Homero Gutierrez-Aguirre, Cesar
    Carlos Jaime-Perez, Jose
    Hematology, 2016, 21 (07) : 411 - 414
  • [49] Nilotinib as first-line therapy for chronic myeloid leukemia
    Vaid, A.
    INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 438 - 445
  • [50] Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study
    Etienne, Gabriel
    Huguet, Francoise
    Guerci-Bresler, Agnes
    Nicolini, Franck E.
    Maloisel, Frederic
    Coiteux, Valerie
    Dauriac, Charles
    Carpentier, Nathalie
    Bourdeix, Isabelle
    Tulliez, Michel
    Cony-Makhoul, Pascale
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 71 - 80
12345